ReviewJournal of dental research2015
Diabetes as a risk factor for medication-related osteonecrosis of the jaw.
Review in Journal of dental research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 4 syntheses or guidelines pooled it, 115 citations in OpenAlex.
- No evidence of genetic causality between diabetes and osteonecrosis: a bidirectional two-sample Mendelian randomization analysis.Journal of orthopaedic surgery and research · 2023Pooled it
- Medication-Related Osteonecrosis of the Jaw: A Systematic Review and a Bioinformatic Analysis.International journal of molecular sciences · 2023Pooled it
- Are medication-induced salivary changes the culprit of osteonecrosis of the jaw? A systematic review.Frontiers in medicine · 2023Pooled it
- Does Diabetes Mellitus Increase the Risk of Avascular Osteonecrosis? A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2022Pooled it
- Periodontitis and Glycaemic Dyscontrol Substantially Increase the Risk of Medication-Related Osteonecrosis of the Jaw: A Preclinical Study in Female Rats.Journal of clinical medicine · 2026Article
- Medication-related osteonecrosis of the jaw in multiple myeloma patients: a case series.British dental journal · 2026Article
- Successful prevention of medication-related osteonecrosis of the jaw after dental extractions by socket preservation with alloplast plus tetracycline in patients taking antiresorptive drugs.Journal of dental sciences · 2026Article
- Mesenchymal Stem Cells in Socket Healing and MRONJ.Orthodontics & craniofacial research · 2025Review
- [Medication-related osteonecrosis of the jaw (MRONJ) during the treatment of cancer patients].Magyar onkologia · 2025Review
- Bisphosphonates with high bone-resorption-capacity promote osteonecrosis of the jaw development after tooth extraction in mice.Journal of bone and mineral metabolism · 2025Article
- A case series and review of canine idiopathic osteonecrosis of the jaw.Frontiers in veterinary science · 2025Article
- Chinese expert consensus on the diagnosis and clinical management of medication-related osteonecrosis of the jaw.Journal of bone oncology · 2024Review
- Diagnostic and Therapeutic Approaches to Jaw Osteoradionecrosis.Diagnostics (Basel, Switzerland) · 2024Review
- Platelet-Rich Fibrin Treatment Evaluation in Patients with Medication-Related Osteonecrosis of the Jaw and Osteoradionecrosis.Journal of clinical medicine · 2024Article
- Review
- Reepithelialization of Diabetic Skin and Mucosal Wounds Is Rescued by Treatment With Epigenetic Inhibitors.Diabetes · 2024Article
- Review
- Use of Leukocyte- and Platelet-Rich Fibrin to Prevent Osteonecrosis of the Jaws Associated with the Use of Bisphosphonate Therapy: A Case Series.Journal of maxillofacial and oral surgery · 2023Article
- Antiresorptive Versus Anabolic Therapy in Managing Osteoporosis in People with Type 1 and Type 2 Diabetes.JBMR plus · 2023Review
- Osteonecrosis of the Jaws: An Update and Review of Literature.Journal of maxillofacial and oral surgery · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medication-related osteonecrosis of the jaw (MRONJ) is a severe devastating complication for which the exact pathogenesis is not completely understood. Multiple systemic and local factors may contribute to the development of MRONJ. A growing body of evidence supports diabetes mellitus (DM) as an important risk factor for this complication; however, the exact mechanism by which DM may promote MRONJ has yet to be determined. The current review elucidates the role of DM in the pathogenesis of MRONJ and the mechanisms by which DM may increase the risk for MRONJ. Factors related to DM pathogenesis and treatment may contribute to poor bone quality through multiple damaged pathways, including microvascular ischemia, endothelial cell dysfunction, reduced remodeling of bone, and increased apoptosis of osteoblasts and osteocytes. In addition, DM induces changes in immune cell function and promotes inflammation. This increases the risk for chronic infection in the settings of cancer and its treatment, as well as antiresorptive medication exposure, thus raising the risk of developing MRONJ. A genetic predisposition for MRONJ, coupled with CYP 450 gene alterations, has been suggested to affect the degradation of medications for DM such as thiazolidinediones and may further increase the risk for MRONJ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.